The offering provides a cash infusion to fund TUDRIQEV's commercial launch and pipeline, but the ~13% immediate dilution and the Baker Brothers overhang from the shelf registration file 3 weeks ago create near-term selling pressure. Monitor the September 15 annual meeting for the authorized share count increase vote (150M to 300M), failure would constrain future financing. With a ~28% short interest, the accelerated approval catalyst may have already been priced in; the real binary event is the IGNYTE-3 confirmatory trial data.
Drug in focus
REPL drug pipeline →TUDRIQEV
● Neutral Named in this 424B5- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved and commercially available in the U.S. since October 2026.
- Next catalyst
- None dated
What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $13.67entry
- T+1 · 3mo ago −0.15%α +0.17% · $13.65
- T+5 · 3mo ago +7.02%α +7.07% · $14.63
- T+20 · 2mo ago +8.05%α +8.96% · $14.77
- T+60 · 14d ago +51.06%α +53.48% · $20.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Replimune Group is conducting a $150 million underwritten public offering of 9,701,490 shares of common stock and pre-funded warrants to purchase 2,736,340 shares, priced at $12.06 per share, at-the-market. Net proceeds of ~$140.5 million will fund the commercial launch of TUDRIQEV (RP1), recently granted accelerated FDA approval, and continued development of the RPx platform. The offering was taken down from a shelf registration filed 17 days ago that had flagged a 30% overhang from Baker Brothers affiliates' resale registration and a going-concern warning with cash runway only through Q1 2027. This dilutive capital raise adds near-term downside, extending the runway but at the cost of ~13% dilution to existing shareholders, while the company has never generated product revenue and faces ongoing confirmatory trial requirements for TUDRIQEV's accelerated approval.
Key Facts
- Offering of 9,701,490 shares of common stock at $12.06 per share and pre-funded warrants to purchase 2,736,340 shares at $12.0599 each
- Total offering size: $149,999,956; net proceeds to company: ~$140.5 million
- Pro forma shares outstanding post-offering: 92,418,413 (excluding new pre-funded warrant shares of 2,736,340)
- Immediate dilution of $9.18 per share to new investors (76% dilution from offering price to as-adjusted net tangible book value of $2.88)
- Net tangible book value before offering: $166.2 million ($1.72 per share); after offering: $306.7 million ($2.88 per share)
- FDA granted accelerated approval of TUDRIQEV (RP1) on August 6, 2026, for advanced melanoma post anti-PD-1 failure
- Going-concern warning: accumulated deficit of $1,262.5M, net loss of $313.9M in FY2026 ended March 31, 2026; cash and short-term investments of $268.9M at March 31, 2026
- Prior S-3/A filing (July 24, 2026) enabled Baker Brothers affiliates to resell up to 25,103,489 shares (~30% of pre-offering outstanding), with company receiving no proceeds
Financial Impact
Dilution of ~13% from new shares plus pre-funded warrants. Net proceeds of ~$140.5M extended cash runway by ~5-6 months at current burn rate; prior cash runway through Q1 2027 was the concern.
Risk Factors
- Dilution from new shares and pre-funded warrants, reducing EPS and ownership percentages
- Going-concern risk persists: annual net loss of $313.9M vs. cash of $268.9M; need for additional capital likely within 12 months
- TUDRIQEV accelerated approval requires confirmatory IGNYTE-3 trial; failure to confirm benefit could lead to FDA withdrawal
- Baker Brothers resale registration overhang of up to 25M shares
- Lock-up on management/insiders expires in 45 days, potentially enabling further selling
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-093040 |
| Document: 0001104659-26-093040-index-headers.html | 0001104659-26-093040 |
| Document: 0001104659-26-093040-index.html | 0001104659-26-093040 |
| Document: 0001104659-26-093040.txt | 0001104659-26-093040 |
Track record
32 reports on REPL
9 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers